I wondering now if we shouldn't now in our thinking be more guided by Dr. Lanza's comment, that when a joint venture happens, it will happen quickly? That, of course suggests putting many of our current issues behind us and ends the talk of bankruptcy.
As you know, chapter 11 would require selling off some of the IP and I don't think Lanza or the Board have any desire to do that, given the realistic promise research that is awaiting clinicals in areas beyond the eye.
JV and buyouts are exploding these days in the biotech sector. while ago, I got all excited about financing from a friendly SHIRE as e seemed, and still do, a perfect fit given their investment objectives and what ACTC is all about. Time will tell.
Unknowns, but incredible promise for management and the ACTC Board to continue to nurture us along to commercialization.
We're not talking $1.00 packages of bandages here!
News 
Market Data 
Discover 
